Molecular Genetic Analysis of Oligodendroglial Tumors

Abstract Deletions on the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q) are molecular hallmark lesions of oligodendroglial tumors. Ever since oligodendroglial tumors with 1p and 19q deletions were shown to respond to chemotherapy, neuropathologists have been facing increasing requests for such molecular analysis. Therefore, there is increasing demand for reliable and simple assays. This brief report compiles information on different technical approaches, including manual and automated loss of heterozygosity analysis, fluorescence in situ hybridization techniques, and quantitative polymerase chain reaction. Herein we present a detailed protocol describing loss of heterozygosity analysis with microsatellite markers currently in use for two multicenter studies.

[1]  G. Barnett,et al.  Characterization of the 1p/19q Chromosomal Loss in Oligodendrogliomas Using Comparative Genomic Hybridization Arrays (CGHa) , 2004, Journal of neuropathology and experimental neurology.

[2]  D. Horsman,et al.  Loss of Heterozygosity for Loci on Chromosome Arms 1p and 10q in Oligodendroglial Tumors: Relationship to Outcome and Chemosensitivity , 2003, Journal of Neuro-Oncology.

[3]  H. Budka,et al.  Fluorescent In Situ Hybridization on Isolated Tumor Cell Nuclei: A Sensitive Method for 1p and 19q Deletion Analysis in Paraffin-Embedded Oligodendroglial Tumor Specimens , 2003, Modern Pathology.

[4]  M. J. van den Bent,et al.  Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features , 2003, Cancer.

[5]  David N Louis,et al.  Oligodendroglioma: Toward Molecular Definitions in Diagnostic Neuro‐Oncology , 2003, Journal of neuropathology and experimental neurology.

[6]  B. Scheithauer,et al.  Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Brat,et al.  Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. , 2003, Frontiers in bioscience : a journal and virtual library.

[8]  Andreas von Deimling,et al.  Impact of Genotype and Morphology on the Prognosis of Glioblastoma , 2002, Journal of neuropathology and experimental neurology.

[9]  Rebecca A Betensky,et al.  Histopathological‐Molecular Genetic Correlations in Referral Pathologist‐Diagnosed Low‐Grade “Oligodendroglioma” , 2002, Journal of neuropathology and experimental neurology.

[10]  Robert B. Jenkins,et al.  Losses of Chromosomal Arms 1p and 19q in the Diagnosis of Oligodendroglioma. A Study of Paraffin-Embedded Sections , 2001, Modern Pathology.

[11]  K. Aldape,et al.  Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. , 2001, The American journal of pathology.

[12]  D. Louis,et al.  Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. , 2000, Journal of neurosurgery.

[13]  B. Scheithauer,et al.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. McLendon,et al.  Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. , 1999, The American journal of pathology.

[15]  B. Scheithauer,et al.  Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype , 1999, Oncogene.

[16]  A. von Deimling,et al.  Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. , 1999, Journal of neuropathology and experimental neurology.

[17]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[18]  J. Rey,et al.  Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors , 1995, International journal of cancer.

[19]  D. Louis,et al.  Shared Allelic Losses on Chromosomes 1p and 19q Suggest a Common Origin of Oligodendroglioma and Oligoastrocytoma , 1995, Journal of neuropathology and experimental neurology.

[20]  G. Reifenberger,et al.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. , 1994, The American journal of pathology.

[21]  R. Wellenreuther,et al.  Loci associated with malignant progression in astrocytomas: a candidate on chromosome 19q. , 1994, Cancer research.

[22]  A. von Deimling,et al.  A device for processing large acrylamide gels. , 1994, BioTechniques.

[23]  D. Louis,et al.  A rapid and non‐radioactive PCR based assay for the detection of allelic loss in human gliomas , 1993, Neuropathology and applied neurobiology.

[24]  B. Scheithauer,et al.  Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas , 1992, Genes, chromosomes & cancer.

[25]  D. Louis,et al.  A (CA)n dinucleotide repeat assay for evaluating loss of allelic heterozygosity in small and archival human brain tumor specimens. , 1992, The American journal of pathology.

[26]  I. Petersen,et al.  Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. , 1992, Cancer research.